5 Conclusion
In conclusion, although our meta-analysis showed little difference between the prevalence of SARS-CoV-2 infections in patients with ARDs and the global prevalence of SARS-CoV-2 infections, the prevalence of COVID-19 in PsA was significantly higher than the global prevalence. The use of DMARDs could reduce the risk of being infected with COVID-19, but the use of GC increased this risk. csDMARDs were associated with disease severity in COVID-19. bDMARDs, especially anti-TNF, were associated with a reduced risk of severe disease. GC is effective in patients with severe COVID-19-related respiratory failure but may not have a benefit in patients with early or mild disease.